HPV vaccine shows promise in preventing cervical cancer for HIV-Positive women

NCT ID NCT03284866

Completed Disease control Sponsor: AIDS Malignancy Consortium Source: ClinicalTrials.gov ↗

First seen Jan 30, 2026 · Last updated May 20, 2026 · Updated 14 times

Summary

This study tested whether the HPV vaccine can reduce high-grade cervical lesions (precancerous changes) in 536 women living with HIV. Participants received either the HPV vaccine or a placebo, and researchers tracked new lesions over one to two years. The goal was to see if the vaccine helps the immune system fight HPV and prevent cervical cancer in this high-risk group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

African Cancer Institute at Stellenbosch

Cape Town, South Africa
Moi University School of Medicine

Eldoret, Kenya
UNC Project Malawi

Lilongwe, Malawi
Uganda Cancer Institute

Kampala, Uganda
University of Zimbabwe

Harare, Zimbabwe
University of the Witwatersrand

Johannesburg, South Africa

Conditions

Explore the condition pages connected to this study.